查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067727

美國非侵入性癌症診斷市場規模、佔有率和趨勢分析報告：按產品、技術、適應症、最終用戶和細分市場預測（2026-2033 年）

U.S. Non-Invasive Cancer Diagnostics Market Size, Share, & Trends Analysis Report By Product (Pathology-based Instruments, Imaging Instruments), By Technology, By Indication, By End User, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國非侵入性癌症診斷市場概覽

美國非侵入性癌症診斷市場預計在 2025 年達到 270.8 億美元，預計到 2033 年將達到 475.2 億美元，2026 年至 2033 年的複合年成長率為 7.4%。

這一成長是由診斷技術的不斷進步、癌症發病率的上升以及公立和私立機構為改善早期檢測和治療而加大的力度所推動的。

美國無創癌症診斷產業的成長正受到各公司策略擴張措施的進一步推動，這些措施旨在增強其商業化和創新能力。例如，Dxcover於2025年6月在納許維爾設立了美國總部，以加速其人工智慧癌症檢測產品PANAROMIC在美國（全球最大的生命科學市場）的商業化進程。新總部將支援夥伴關係、本地生產以及研發，從而強化公司無創且經濟高效的癌症篩檢平台，並拓展其早期檢測能力。

此外，人們對能夠改善患者預後的早期、準確且微創的檢測方法的需求日益成長。血液檢測和多癌種篩檢技術的進步進一步促進了及時診斷，並推動了這些技術在臨床上的廣泛應用。例如，Exact Sciences公司於2025年9月推出了Cancerguard，這是美國首個多癌症種早期檢測血液檢測產品。此檢測可透過多種生物標記物識別50多種癌症。 Cancerguard旨在解決早期診斷的難題，展現出高靈敏度和特異性。預計與現有篩檢方法結合使用時，它將有助於更早發現癌症，並改善治療效果。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：美國非侵入性癌症診斷市場：影響因素、趨勢與市場規模

  • 市場譜系展望
  • 市場動態
  • 美國非侵入性癌症診斷市場分析工具
  • 美國非侵入性癌症診斷市場：研發管線分析

第4章：美國非侵入性癌症診斷市場：基於產品的估算和趨勢分析

  • 美國非侵入性癌症診斷市場：基於產品的波動分析
  • 市場規模、預測與趨勢分析：按產品分類，2021-2033 年
  • 裝置
    • 病理檢測設備
    • 影像設備
  • 消耗品
  • 試劑盒和試劑

第5章：美國非侵入性癌症診斷市場：依技術分類的估算與趨勢分析

  • 美國非侵入性癌症診斷市場：基於技術的波動分析
  • 市場規模、預測與趨勢分析：按技術分類，2021-2033 年
  • 影像
  • 液態切片
  • 免疫檢測

第6章 非侵入性癌症診斷市場：按適應症分類的業務分析

  • 美國非侵入性癌症診斷市場：按適應症分類的波動分析
  • 市場規模、預測與趨勢分析：按適應症分類，2021-2033 年
  • 肺癌
  • 乳癌
  • 結腸癌
  • 攝護腺癌
  • 血癌
  • 肝癌
  • 子宮頸癌
  • 皮膚癌
  • 其他（甲狀腺癌等）

第7章 非侵入性癌症診斷市場：按最終用戶分類的業務分析

  • 美國非侵入性癌症診斷市場：按最終用戶分類的波動分析
  • 市場規模、預測與趨勢分析：按最終用戶分類，2021-2033 年
  • 醫院
  • 診斷實驗室
  • 其他（學術/研究機構等）

第8章 競爭情勢

  • 主要市場參與企業的最新趨勢及影響分析
  • 公司和競爭對手的分類
  • 供應商情況
    • 主要公司熱力圖分析，2025 年
  • 公司簡介
    • Abbott Laboratories
    • GE Healthcare
    • Siemens Healthineers AG
    • Koninklijke Philips NV
    • Canon Medical Systems
    • F. Hoffmann-La Roche Ltd
    • Illumina, Inc.
    • Guardant Health, Inc.
    • Thermo Fisher Scientific Inc.
    • FONAR Corporation
Product Code: GVR-4-68040-911-6

U.S. Non-Invasive Cancer Diagnostics Market Summary

The U.S. non-invasive cancer diagnostics market size was estimated at USD 27.08 billion in 2025 and is projected to reach USD 47.52 billion in 2033, growing at a CAGR of 7.4% from 2026 to 2033. The growth is driven by the continuous advancements in diagnostic technologies, the rising prevalence of cancer, and increasing initiatives by both private and public organizations aimed at enhancing early detection and treatment.

The U.S. non-invasive cancer diagnostics industry's growth is further driven by strategic expansion initiatives by companies to strengthen commercialization and innovation capabilities. For instance, in June 2025, Dxcover launched its U.S. headquarters in Nashville to accelerate the commercialization of its AI-powered PANAROMIC cancer test in the world's largest life sciences market. The new facility will support partnerships, local manufacturing, and R&D, strengthening its non-invasive, cost-effective cancer screening platform and expanding early detection capabilities.

In addition, increasing demand for early, accurate, and minimally invasive detection methods that improve patient outcomes. Advancements in blood-based and multi-cancer screening technologies are further supporting timely diagnosis and wider clinical adoption. For instance, in September 2025, Exact Sciences launched Cancerguard, a first-of-its-kind multi-cancer early detection blood test in the U.S., capable of identifying over 50 cancer types through multiple biomarkers. The test aims to address gaps in early diagnosis, demonstrating strong sensitivity and high specificity, and is expected to improve outcomes by enabling earlier detection alongside existing screening methods.

U.S. Non-invasive Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. non-invasive cancer diagnostics market report based on product, technology, indication, and end user:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments
    • Pathology-based Instruments
    • Polymerase Chain Reaction (PCR) Instruments
    • Next-generation Sequencing (NGS) Instruments
    • Microarrays
    • Imaging Instruments
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT)
    • Positron Emission Tomography (PET)
    • Mammography
    • Others (Ultrasound, etc.)
  • Consumables
  • Kits & Reagents
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Imaging
  • Liquid Biopsy
  • Immunoassay
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Blood Cancer
  • Liver Cancer
  • Cervical Cancer
  • Skin Cancer
  • Others (Thyroid Cancer, etc.)
  • End User Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Others (Academic & Research Institutes, etc.)

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Technology
    • 1.2.3. Indication
    • 1.2.4. End User
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Non-Invasive Cancer Diagnostic Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Non-Invasive Cancer Diagnostic Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. U.S. Non-Invasive Cancer Diagnostic Market: Pipeline Analysis

Chapter 4. U.S. Non-Invasive Cancer Diagnostic Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. U.S. Non-Invasive Cancer Diagnostic Market: Product Movement Analysis
  • 4.3. U.S. Non-Invasive Cancer Diagnostic Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Instruments
    • 4.4.1. Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Pathology-based Instruments
      • 4.4.2.1. Pathology-based Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.2. Polymerase Chain Reaction (PCR) Instruments
        • 4.4.2.2.1. Polymerase Chain Reaction (PCR) Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.3. Next-generation Sequencing (NGS) Instruments
        • 4.4.2.3.1. Next-generation Sequencing (NGS) Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.4. Microarrays
        • 4.4.2.4.1. Microarrays Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Imaging Instruments
      • 4.4.3.1. Imaging Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.2. Magnetic Resonance Imaging (MRI)
        • 4.4.3.2.1. Magnetic Resonance Imaging (MRI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.3. Computed Tomography (CT)
        • 4.4.3.3.1. Computed Tomography (CT) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.4. Positron Emission Tomography (PET)
        • 4.4.3.4.1. Positron Emission Tomography (PET) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.5. Mammography
        • 4.4.3.5.1. Mammography Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.6. Others (Ultrasound, etc.)
        • 4.4.3.6.1. Others (Ultrasound, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Consumables
    • 4.5.1. Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Kits & Reagents
    • 4.6.1. Kits & Reagents Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Non-Invasive Cancer Diagnostic Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Segment Dashboard
  • 5.2. U.S. Non-Invasive Cancer Diagnostic Market: Technology Movement Analysis
  • 5.3. U.S. Non-Invasive Cancer Diagnostic Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 5.4. Imaging
    • 5.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 5.5. Liquid Biopsy
    • 5.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 5.6. Immunoassay
    • 5.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 6. Non-Invasive Cancer Diagnostic Market: Indication Business Analysis

  • 6.1. Indication Segment Dashboard
  • 6.2. U.S. Non-Invasive Cancer Diagnostic Market: Indication Movement Analysis
  • 6.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 6.4. Lung Cancer
    • 6.4.1. Lung Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Breast Cancer
    • 6.5.1. Breast Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Colorectal Cancer
    • 6.6.1. Colorectal Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Prostate Cancer
    • 6.7.1. Prostate Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Blood Cancer
    • 6.8.1. Blood Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Liver Cancer
    • 6.9.1. Liver Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Cervical Cancer
    • 6.10.1. Cervical Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Skin Cancer
    • 6.11.1. Skin Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12. Others (Thyroid Cancer, etc.)
    • 6.12.1. Others (Thyroid Cancer, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Non-Invasive Cancer Diagnostic Market: End User Business Analysis

  • 7.1. End User Segment Dashboard
  • 7.2. U.S. Non-Invasive Cancer Diagnostic Market: End User Movement Analysis
  • 7.3. Market Size & Forecasts and Trend Analysis, by End User, 2021 to 2033 (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Diagnostic Laboratories
    • 7.5.1. Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Others (Academic & Research Institutes, etc.)
    • 7.6.1. Others (Academic & Research Institutes, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2025
  • 8.4. Company Profiles
    • 8.4.1. Abbott Laboratories
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. GE Healthcare
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Service benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Siemens Healthineers AG
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Service benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Koninklijke Philips N.V.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Service benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Canon Medical Systems
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Service benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. F. Hoffmann-La Roche Ltd
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Service benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Illumina, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Service benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Guardant Health, Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Service benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Thermo Fisher Scientific Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Service benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. FONAR Corporation
      • 8.4.10.1. Financial performance
      • 8.4.10.2. Service benchmarking
      • 8.4.10.3. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. non-invasive cancer diagnostic market, by product, 2021 - 2033 (USD Million)
  • Table 3 U.S. non-invasive cancer diagnostic market, by technology, 2021 - 2033 (USD Million)
  • Table 4 U.S. non-invasive cancer diagnostic market, by indication, 2021 - 2033 (USD Million)
  • Table 5 U.S. non-invasive cancer diagnostic market, by end user, 2021 - 2033 (USD Million)
  • Table 6 Financial performance
  • Table 7 Key companies undergoing expansions
  • Table 8 Key companies undergoing acquisitions
  • Table 9 Key companies undergoing collaborations
  • Table 10 Key companies launching new products/services
  • Table 11 Key companies undergoing partnerships
  • Table 12 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. non-invasive cancer diagnostic market: market outlook
  • Fig. 10 U.S. non-invasive cancer diagnostic market competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. non-invasive cancer diagnostic market driver impact
  • Fig. 16 U.S. non-invasive cancer diagnostic market restraint impact
  • Fig. 17 U.S. non-invasive cancer diagnostic market strategic initiatives analysis
  • Fig. 18 U.S. non-invasive cancer diagnostic market: product movement analysis
  • Fig. 19 U.S. non-invasive cancer diagnostic market: product outlook and key takeaways
  • Fig. 20 Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Pathology-based instruments market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Polymerase Chain Reaction (PCR) Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Next-generation Sequencing (NGS) Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Microarrays market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Imaging instruments market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Magnetic Resonance Imaging (MRI) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Computed Tomography (CT) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Positron Emission Tomography (PET) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Mammography market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Others (Ultrasound, etc.) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Consumables market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Kits & reagents market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. non-invasive cancer diagnostic market: by technology, movement analysis
  • Fig. 34 U.S. non-invasive cancer diagnostic market: technology outlook and key takeaways
  • Fig. 35 Imaging market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Liquid biopsy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Immunoassay market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 U.S. non-invasive cancer diagnostic market: by indication, movement analysis
  • Fig. 39 U.S. non-invasive cancer diagnostic market: indication outlook and key takeaways
  • Fig. 40 Lung cancer market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Breast cancer market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Colorectal cancer market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Prostate market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Blood market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Liver market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Cervical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Skin market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Others (Thyroid Cancer, etc.) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 U.S. non-invasive cancer diagnostic market: by end user, movement analysis
  • Fig. 50 U.S. non-invasive cancer diagnostic market: end user outlook and key takeaways
  • Fig. 51 Hospitals market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Diagnostic laboratories market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Others (Academic & Research Institutes, etc.) market estimates and forecasts, 2021 - 2033 (USD Million)